Global Endometrial Cancer Therapeutics Market 2018-2022

The global endometrial cancer therapeutics market is predicted to reach a size of more than USD 24 billion by 2022 with the rise in adoption of immune therapy in the treatment of endometrial cancer. Wondering how to make the most of this flourishing industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global endometrial cancer therapeutics market. It also examines the competitive landscape and some vendors that include CELGENE, Janssen Pharmaceuticals, and Novartis.

Get an impression below about how you can gain compelling insights from Technavio’s market research report? Check out more about the endometrial cancer treatment industry

The global endometrial cancer therapeutics market is expected to grow at a CAGR of more than 5% during the forecast period

Endometrial cancer therapeutics industry growth is expected to accelerate over the next five years, driven by increasing prevalence of endometrial cancer. The Americas will drive more than 43% of the growth of the endometrial cancer treatment industry, while EMEA and APAC are also predicted to make significant contributions to the incremental growth in the forecast period. According to an article published by National Center for Biotechnology Information (NCBI) in 2017, around 60,050 cases of endometrial cancer were diagnosed in the US. The Americas held the largest market share in 2017 followed by EMEA and APAC. However, APAC and EMEA are likely to witness a larger growth during the forecast period than the Americas. Technavio’s endometrial cancer therapeutics industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Growing cases of endometrial cancer will drive the growth of the market

Endometrial cancer is regarded as one of the most common gynecological malignancies, and the rate of incidence of this type of uterine cancer is growing rapidly across the globe. The number of drug molecules in the pipeline for endometrial cancer treatment is increasing at a significant pace which is expected to foster the growth of the endometrial cancer therapeutics market. Around 80% of all endometrial cancer incidences are caused by factors such as high exposure to estrogen, changing lifestyle, and socioeconomic factors that are surging the rate of prevalence. This rapidly growing rate of prevalence of endometrial cancer is expected to drive the demand for treatment of endometrial cancer over the coming five-year period.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services. Start your 14-day FREE trial

CELGENE, Janssen Pharmaceuticals, and Novartis are among the leading vendors

Most of the leading vendors in the global endometrial cancer therapeutics market are expected to undertake clinical trials for immune therapies as this therapy works by hindering or slowing the growth of cancer cells. Many companies are engaging in mergers and acquisitions to fortify their position in the global endometrial cancer therapeutics market. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• CELGENE
• Janssen Pharmaceuticals
• Novartis
• Pfizer
• Teva Pharmaceutical Industries

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch